rs10758669 — JAK2

JAK2 rs10758669 — Gut Barrier Integrity and IBD Susceptibility

The JAK2 gene encodes Janus Kinase 2, a critical signal transduction enzyme in the JAK-STAT pathway¹¹ JAK-STAT pathway
A signaling cascade where cytokine binding activates Janus kinases, which phosphorylate STAT transcription factors to regulate gene expression controlling immunity, cell growth, and barrier function. The rs10758669 variant sits in an intergenic region near JAK2 on chromosome 9p24 and was first identified as a Crohn's disease susceptibility locus in a landmark GWAS²² first identified as a Crohn's disease susceptibility locus in a landmark GWAS
Barrett et al. identified JAK2 among 21 new CD susceptibility regions in a study of 3,230 cases and 4,829 controls, subsequently confirmed for both Crohn's disease and ulcerative colitis across multiple populations. The C allele increases JAK2 expression in immune cells, amplifying inflammatory signaling and compromising the intestinal barrier that normally prevents bacterial translocation into deeper tissue.

The Mechanism

Unlike coding variants that alter protein structure, rs10758669 is a regulatory variant that influences how much JAK2 protein is produced. Macrophages from CC risk carriers show significantly increased JAK2 mRNA and protein expression compared to AA carriers³³ Macrophages from CC risk carriers show significantly increased JAK2 mRNA and protein expression compared to AA carriers
Hedl & Abraham showed that CC carriers demonstrate increased JAK2 expression and elevated NOD2-induced JAK2 phosphorylation, with CA carriers showing intermediate levels. This gain-of-function effect amplifies JAK-STAT signaling downstream of innate immune receptors like NOD2, shifting the cytokine balance toward pro-inflammatory responses.

The consequences for gut barrier function are direct. The JAK-STAT pathway regulates expression and localization of tight junction proteins that seal the spaces between intestinal epithelial cells. Overactive JAK-STAT signaling upregulates claudin-2⁴⁴ claudin-2
A pore-forming tight junction protein; higher levels increase paracellular permeability to ions and small molecules, which creates channels that increase paracellular permeability. Simultaneously, it reduces expression and mislocates barrier-forming proteins like ZO-1, occludin, and JAM-A, weakening the leak pathway that normally restricts passage of larger molecules. The result is increased intestinal permeability — the measurable functional consequence demonstrated in rs10758669 C allele carriers.

The Evidence

A meta-analysis of 11 studies encompassing 7,009 CD patients, 7,929 UC patients, and 19,235 controls⁵⁵ A meta-analysis of 11 studies encompassing 7,009 CD patients, 7,929 UC patients, and 19,235 controls
Zhang et al. found the C allele was a risk factor for both Crohn's disease and ulcerative colitis, especially in Caucasian populations established the association firmly. For Crohn's disease, CC homozygotes face an OR of 1.29 (95% CI: 1.17-1.43) versus AA, while AC heterozygotes show OR 1.16 (95% CI: 1.08-1.24). For ulcerative colitis, the effects are comparable: CC versus AA OR 1.33 (95% CI: 1.20-1.47), AC versus AA OR 1.14 (95% CI: 1.06-1.22). The association is strongest in Caucasian populations, with no significant effect observed in Asian cohorts.

Prager et al. directly demonstrated the barrier dysfunction mechanism⁶⁶ Prager et al. directly demonstrated the barrier dysfunction mechanism
In 464 CD patients, 292 UC patients, and 508 controls, C allele carriers showed increased intestinal permeability measured by lactulose/mannitol ratio during CD remission (p=0.004). This is significant because permeability was measured during remission, meaning the barrier defect persists independently of active inflammation. The overall OR for CD association was 1.25 (95% CI: 1.04-1.50).

Functional studies revealed the gain-of-function mechanism⁷⁷ Functional studies revealed the gain-of-function mechanism
CC carriers' macrophages demonstrate increased NOD2-induced JAK2 phosphorylation and altered pro-inflammatory cytokine secretion, with autocrine IL-10, IL-4, IL-22, and TSLP cooperatively suppressing pro-inflammatory responses through JAK-dependent feedback loops — loops that become amplified with the C allele.

Practical Implications

The clinical relevance of this variant is twofold: it identifies individuals at increased risk for IBD and, more importantly, it points to intestinal barrier integrity as a targetable mechanism. Unlike variants that affect immune recognition or autophagy, rs10758669 acts through barrier permeability, which can be supported through specific nutritional and lifestyle strategies. L-glutamine is the primary fuel for enterocytes and has been shown to promote tight junction protein expression including ZO-1, claudin-1, and occludin⁸⁸ has been shown to promote tight junction protein expression including ZO-1, claudin-1, and occludin
Glutamine supplementation reversed villus atrophy and restored tight junction protein expression in multiple experimental models. Zinc carnosine stabilizes gut mucosa and has been shown in controlled trials to prevent NSAID-induced permeability increases⁹⁹ has been shown in controlled trials to prevent NSAID-induced permeability increases
A threefold increase in gut permeability from indomethacin was abolished by co-administration of zinc carnosine. Butyrate, a short-chain fatty acid produced by fermenting resistant starch and fiber, tightens epithelial barriers through AMPK-mediated tight junction assembly, facilitating the relocalization of ZO-1 and occludin to cell junctions¹⁰¹⁰ tightens epithelial barriers through AMPK-mediated tight junction assembly, facilitating the relocalization of ZO-1 and occludin to cell junctions.

Importantly, NSAIDs are particularly problematic for carriers of this variant. All conventional NSAIDs increase intestinal permeability within 24 hours of ingestion through mitochondrial uncoupling in enterocytes, compounding the genetically elevated permeability from enhanced JAK-STAT signaling.

The therapeutic context is also noteworthy: JAK inhibitors (tofacitinib, upadacitinib) are now approved for IBD treatment, directly targeting the pathway this variant upregulates. Tofacitinib has been shown to prevent ZO-1 relocalization and reduce claudin-2 expression, essentially reversing the barrier defect at the molecular level.

Interactions

rs10758669 interacts with other IBD susceptibility loci through convergent pathways. NOD2 variants (rs2066844, rs2066845) are particularly relevant because NOD2 signaling directly activates JAK2 phosphorylation — CC carriers with NOD2 risk variants would experience amplified innate immune signaling upon bacterial sensing. ATG16L1 T300A (rs2241880) compounds the risk through a complementary mechanism: impaired autophagy allows bacteria to persist while enhanced JAK-STAT signaling drives excessive inflammatory responses to those bacteria. IRGM (rs13361189) and MST1 (rs3197999) variants further impair bacterial handling and macrophage function, creating a multilayered defect in gut innate immunity when combined with enhanced JAK2 signaling.